Anavex Life Sciences Corp (AVXL)

[Doc328]

As I see it, patients, on placebo or on the drug, will have one of two outcomes; it helps to a degree or it does not help. In both of these outcomes, as long as the drug is safe, the patient will likely ask to continue, to no ones surprise

I agree and this is borne out by facts from AD clinical trials. In the large phase 3 solanezumab (anti-amyloid MAb) studies (EXPEDITION and EXPEDITION2), > 90% of the patients who completed the blinded period rolled over into the Open Label Extension study (EXPEDITION-EXT). In time, the drug was found to have no significant benefit over placebo.